Observer prediction of HER2 amplification in HercepTest 2+ breast cancers as a potential audit instrument

Histopathology

Volumn 59, Issue 2, 2011, Pages 333-335

  Going, James J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Breast cancer; FISH; HER2; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HERCEPTEST; HUMAN; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALUE; PRIORITY JOURNAL;

BREAST NEOPLASMS; COMMISSION ON PROFESSIONAL AND HOSPITAL ACTIVITIES; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 80052237586     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03879.x     Document Type: Article

References (8)

1. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Standardising slide-based assays in breast cancer: hormone receptors, HER2 and sentinel lymph nodes. Clin. Cancer Res. 2007; 13; 2831-2835.
2. Wolff AC, Hammond EH, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25; 118-145.
3. Pritchard KI, Shepherd LE, O'Malley FP et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 2006; 354; 2103-2111.
4. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone-receptor positive breast cancer: Status Report 2004. J. Clin. Oncol. 2005; 23; 619-629.
5. Dowsett M, Houghton J, Iden C et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according to oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann. Oncol. 2006; 17; 818-826.
6. Bartlett JMS, Going JJ, Mallon EA et al. Evaluating HER2 amplification and overexpression in breast cancer. J. Pathol. 2001; 195; 422-428.
7. Dunn C, Mallon EA, Murray LS et al. Her-2 testing in breast cancer: observer effects and associations with histopathology. J. Pathol. 2006; 210;.
8. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007; 25; 5287-5312.